CA2490544A1 - Minimally compliant, volume efficient piston for osmotic drug delivery systems - Google Patents
Minimally compliant, volume efficient piston for osmotic drug delivery systems Download PDFInfo
- Publication number
- CA2490544A1 CA2490544A1 CA002490544A CA2490544A CA2490544A1 CA 2490544 A1 CA2490544 A1 CA 2490544A1 CA 002490544 A CA002490544 A CA 002490544A CA 2490544 A CA2490544 A CA 2490544A CA 2490544 A1 CA2490544 A1 CA 2490544A1
- Authority
- CA
- Canada
- Prior art keywords
- piston
- osmotic
- agent
- interior
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M2005/14513—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons with secondary fluid driving or regulating the infusion
Abstract
An osmotic pump having a minimally compliant, volume efficient piston positioned within a capsule. The capsule has an interior surface, a benefici al agent, and an osmotic agent. The piston is movable with respect to an interi or surface of the capsule, and defines a movable seal with the interior surface of the capsule. The movable seal separates the osmotic agent from the beneficial agent. The piston has a length to total diameter ratio of about 1.1:1 and a core diameter to total diameter ratio of about 0.9:1. The piston enables greater beneficial agent and/or osmotic agent payload without increasing the size of the capsule. The osmotic agent imbibes liquid from a surrounding environment through a semipermeable body to cause the piston to move and in turn cause delivery of the beneficial agent from the capsule.</S DOAB>
Claims (16)
1. An osmotic delivery system comprising:
a capsule, said capsule having an interior for holding a beneficial agent, said interior having an interior surface;
an osmotic agent located in said interior;
a semipermeable body in liquid communication with said capsule for permitting liquid to permeate through said semipermeable body to said osmotic agent; and a piston having a length to total diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1 located within said interior of said capsule, being movable with respect to said interior surface of said capsule, defining a movable seal with said interior surface of said capsule that separates said osmotic agent from the beneficial agent;
said osmotic agent located between said piston and said semipermeable body, said osmotic agent for imbibing fluid from a surrounding environment through said semipermeable body to cause said piston to move and in turn cause delivery of the beneficial agent from said capsule.
a capsule, said capsule having an interior for holding a beneficial agent, said interior having an interior surface;
an osmotic agent located in said interior;
a semipermeable body in liquid communication with said capsule for permitting liquid to permeate through said semipermeable body to said osmotic agent; and a piston having a length to total diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1 located within said interior of said capsule, being movable with respect to said interior surface of said capsule, defining a movable seal with said interior surface of said capsule that separates said osmotic agent from the beneficial agent;
said osmotic agent located between said piston and said semipermeable body, said osmotic agent for imbibing fluid from a surrounding environment through said semipermeable body to cause said piston to move and in turn cause delivery of the beneficial agent from said capsule.
2. The osmotic delivery system according to Claim 1, wherein said piston includes one or a plurality of ribs for effecting said seal with said interior surface.
3. The osmotic delivery system according to Claim 1, wherein said capsule includes a cylindrical tube.
4. The osmotic delivery system according to Claim 3, wherein said cylindrical tube includes an opening and said semipermeable body includes a semipermeable plug, said semipermeable plug located within said opening.
5. The osmotic delivery system according to Claim 1, wherein said osmotic agent includes a tablet.
6. An osmotic delivery system comprising:
a piston having a length to overall diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1;
an osmotic agent; and an enclosure having an interior holding said piston and said osmotic agent, said piston being movable with respect to said enclosure, and said enclosure having a semipermeable body in liquid communication with said osmotic agent for permitting liquid to permeate through said semipermeable body to said osmotic agent, said osmotic agent for imbibing fluid from a surrounding environment and causing said piston to move.
a piston having a length to overall diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1;
an osmotic agent; and an enclosure having an interior holding said piston and said osmotic agent, said piston being movable with respect to said enclosure, and said enclosure having a semipermeable body in liquid communication with said osmotic agent for permitting liquid to permeate through said semipermeable body to said osmotic agent, said osmotic agent for imbibing fluid from a surrounding environment and causing said piston to move.
7. The osmotic delivery system according to Claim 6, wherein said interior of said enclosure includes an interior surface, said piston abutting against said interior surface.
8. The osmotic delivery system according to Claim 6, wherein said semipermeable body is located within said interior of said enclosure.
9. The osmotic delivery system according to Claim 6, wherein said enclosure is fluid impermeable.
10. The osmotic delivery system according to Claim 6, wherein said osmotic agent is located between said semipermeable body and said piston.
11. The osmotic delivery system according to Claim 6, further comprising a beneficial agent located in said interior of said enclosure, said beneficial agent being delivered from said enclosure when said piston moves.
12. The osmotic delivery system according to Claim 6, wherein said piston is fluid impermeable.
13. The osmotic delivery system according to Claim 6, wherein said piston includes at least one rib for effecting a movable seal with said enclosure.
14. The osmotic delivery system according to Claim 6, further comprising a beneficial agent located in said interior of said enclosure, said piston defining a movable seal that separates said osmotic agent from said beneficial agent.
15. An osmotic delivery system comprising:
a capsule having a tubular interior, said tubular interior having an interior surface;
a semipermeable body located at least partially within said tubular interior;
an osmotic agent located between said semipermeable body and said piston;
a beneficial agent located within said tubular interior; and a piston located within said tubular interior, said piston having a length to overall diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1, said piston separating said beneficial agent from said osmotic agent, and being movable with respect to said interior surface of said tubular interior and with respect to said semipermeable body.
a capsule having a tubular interior, said tubular interior having an interior surface;
a semipermeable body located at least partially within said tubular interior;
an osmotic agent located between said semipermeable body and said piston;
a beneficial agent located within said tubular interior; and a piston located within said tubular interior, said piston having a length to overall diameter ratio of about 1.1:1 and a core diameter to overall diameter ratio of about 0.9:1, said piston separating said beneficial agent from said osmotic agent, and being movable with respect to said interior surface of said tubular interior and with respect to said semipermeable body.
16. The osmotic delivery system according to Claim 15, wherein the piston includes at least one rib.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39200402P | 2002-06-26 | 2002-06-26 | |
US60/392,004 | 2002-06-26 | ||
PCT/US2003/020130 WO2004002565A1 (en) | 2002-06-26 | 2003-06-25 | Minimally compliant, volume efficient piston for osmotic drug delivery systems |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2490544A1 true CA2490544A1 (en) | 2004-01-08 |
CA2490544C CA2490544C (en) | 2011-04-19 |
Family
ID=30000792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2490544A Expired - Fee Related CA2490544C (en) | 2002-06-26 | 2003-06-25 | Minimally compliant, volume efficient piston for osmotic drug delivery systems |
Country Status (20)
Country | Link |
---|---|
US (3) | US6939556B2 (en) |
EP (1) | EP1551493B1 (en) |
JP (1) | JP4485945B2 (en) |
KR (1) | KR101046903B1 (en) |
CN (1) | CN100453130C (en) |
AT (1) | ATE376854T1 (en) |
AU (1) | AU2003256308B2 (en) |
BR (1) | BR0312429A (en) |
CA (1) | CA2490544C (en) |
DE (1) | DE60317225T2 (en) |
EC (1) | ECSP055578A (en) |
ES (1) | ES2295642T3 (en) |
HK (1) | HK1080402A1 (en) |
IL (1) | IL165975A (en) |
MX (1) | MXPA05000224A (en) |
NO (1) | NO20050368L (en) |
NZ (1) | NZ537628A (en) |
TW (1) | TW200531709A (en) |
WO (1) | WO2004002565A1 (en) |
ZA (1) | ZA200500744B (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY125870A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
JP2006512370A (en) * | 2002-12-19 | 2006-04-13 | アルザ・コーポレーション | A stable non-aqueous single phase gel and its formulation for delivery from an implantable device |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
AR043809A1 (en) * | 2003-03-31 | 2005-08-17 | Alza Corp | OSMOTIC PUMP WITH MEDIUM TO DISSIP INTERNAL PRESSURE |
KR20050120767A (en) * | 2003-03-31 | 2005-12-23 | 알자 코포레이션 | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
MXPA06003065A (en) * | 2003-11-06 | 2006-05-31 | Alza Corp | Modular imbibition rate reducer for use with implantable osmotic pump. |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
BRPI0518483A2 (en) | 2004-11-23 | 2008-11-18 | Neuromolecular Pharmaceuticals Inc | A composition comprising a controlled release matrix or coating and an nmda receptor antagonist, a method of administering such an nmda antagonist to a patient. |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP1845968A2 (en) | 2004-11-24 | 2007-10-24 | Neuromolecular Pharmaceuticals, Inc | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease |
WO2006084141A2 (en) * | 2005-02-03 | 2006-08-10 | Intarcia Therapeutics, Inc | Suspension formulation of interferon |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US7959938B2 (en) | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
JP5666087B2 (en) * | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Methods and compositions for the treatment of CNS related diseases |
EP1948183B1 (en) * | 2005-10-13 | 2013-12-18 | Duke University | Compositions for the treatment and prevention of heart disease and methods of using same |
DE602007009377D1 (en) * | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM |
KR101200728B1 (en) * | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | Osmotic delivery system and piston assemblies |
AU2008244523B2 (en) * | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
US8105261B2 (en) * | 2007-07-02 | 2012-01-31 | Cardiac Pacemakers, Inc. | Osmotic devices and methods for diuretic therapy |
US8394644B2 (en) | 2007-11-08 | 2013-03-12 | Honeywell International Inc. | Microfluidic osmotic pump |
EP2240155B1 (en) * | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
KR101419583B1 (en) * | 2008-10-15 | 2014-07-25 | 인타르시아 세라퓨틱스 인코포레이티드 | Highly concentrated drug particles, formulations, suspensions and uses thereof |
AU2010265866B2 (en) * | 2009-06-26 | 2012-07-12 | Taris Biomedical Llc | Solid drug tablets for implantable drug delivery devices |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
KR20120100964A (en) | 2009-09-30 | 2012-09-12 | 바이타패스 제네틱스 인코포레이티드 | Cofactors and methods for use for individuals |
CN102883601A (en) | 2009-12-02 | 2013-01-16 | 阿达玛斯医药公司 | Amantadine compositions and methods of use |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
MX2014000419A (en) | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Compositions and methods for modulating metabolic pathways. |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
CA2991909C (en) * | 2012-10-12 | 2020-12-29 | Eli Lilly And Company | Process and device for delivery of fluid by chemical reaction |
CN108452311A (en) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | Composition for enhancing energetic supersession and method |
CN105101958B (en) | 2013-01-15 | 2019-05-17 | 纽斯尔特科学公司 | Treat tuberculosis shape |
EP2964310A1 (en) * | 2013-03-05 | 2016-01-13 | TARIS Biomedical LLC | Drug delivery devices and methods for controlled drug release through device orifice |
CN105228627B (en) | 2013-03-15 | 2018-07-13 | 纽斯尔特科学公司 | Leucine and niacin reduce lipid level |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
CN106456997B (en) | 2014-02-27 | 2018-12-28 | 纽斯尔特科学公司 | For reducing or preventing the composition and method of hepatic steatosis |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
KR20240042548A (en) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | Implant placement and removal systems |
SG11201803353PA (en) | 2015-11-05 | 2018-05-30 | Massachusetts Gen Hospital | Intrathecal delivery of nucleic acid sequences encoding abcd1 for treatment of adrenomyeloneuropathy |
MA43532A (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS RELATED TO EPILEPTIC SEIZURES |
MA53353A (en) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
US10406336B2 (en) | 2016-08-03 | 2019-09-10 | Neil S. Davey | Adjustable rate drug delivery implantable device |
AU2017345724B2 (en) | 2016-10-20 | 2024-04-18 | Peptron, Inc. | Methods of delivering a neuroprotective polypeptide to the central nervous system |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
EP3582832A1 (en) | 2017-02-17 | 2019-12-25 | Eli Lilly and Company | Processes and devices for delivery of fluid by chemical reaction |
EP3592376A1 (en) | 2017-03-08 | 2020-01-15 | Intarcia Therapeutics, Inc | Apparatus and methods for administration of a nauseogenic compound from a drug delivery device |
WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
EP3840735A4 (en) * | 2018-08-23 | 2022-06-15 | Baywind Bioventures | Capsule device for delivery of active agent to gastrointestinal tract |
MX2021004185A (en) | 2018-10-11 | 2021-09-08 | Intarcia Therapeutics Inc | Human amylin analog polypeptides and methods of use. |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753651A (en) * | 1982-08-30 | 1988-06-28 | Alza Corporation | Self-driven pump |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4558888A (en) * | 1983-09-19 | 1985-12-17 | Minnesota Mining And Manufacturing Company | Strip of binding tape |
US4874388A (en) | 1987-06-25 | 1989-10-17 | Alza Corporation | Multi-layer delivery system |
US5728088A (en) * | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US4969884A (en) | 1988-12-28 | 1990-11-13 | Alza Corporation | Osmotically driven syringe |
US5234424A (en) * | 1988-12-28 | 1993-08-10 | Alza Corporation | Osmotically driven syringe |
US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5030216A (en) * | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
US5324280A (en) * | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5180591A (en) * | 1990-07-11 | 1993-01-19 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
US5861166A (en) * | 1991-03-12 | 1999-01-19 | Alza Corporation | Delivery device providing beneficial agent stability |
CN2085662U (en) * | 1991-03-29 | 1991-10-02 | 毕勇 | Productive device for "osmotic pump" of medicines |
US5137727A (en) * | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
DE69229881T2 (en) | 1991-10-04 | 1999-12-09 | Yoshitomi Pharmaceutical | DELAYED RELEASE TABLET |
AU2867492A (en) * | 1991-10-10 | 1993-05-03 | Alza Corporation | Osmotic drug delivery devices with hydrophobic wall materials |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5209746A (en) | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5308348A (en) * | 1992-02-18 | 1994-05-03 | Alza Corporation | Delivery devices with pulsatile effect |
US5456679A (en) * | 1992-02-18 | 1995-10-10 | Alza Corporation | Delivery devices with pulsatile effect |
US5221278A (en) * | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5540665A (en) * | 1994-01-31 | 1996-07-30 | Alza Corporation | Gas driven dispensing device and gas generating engine therefor |
US5458888A (en) * | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5690952A (en) * | 1995-06-07 | 1997-11-25 | Judy A. Magruder et al. | Implantable system for delivery of fluid-sensitive agents to animals |
US6261584B1 (en) * | 1996-02-02 | 2001-07-17 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
ATE284202T1 (en) * | 1996-02-02 | 2004-12-15 | Alza Corp | IMPLANTABLE DELAYED RELEASE SYSTEM |
US6132420A (en) * | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
US6156331A (en) * | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
US6395292B2 (en) * | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
ZA981610B (en) * | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
MY125849A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
MY125870A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
AU1828599A (en) | 1997-12-29 | 1999-07-19 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
ATE260642T1 (en) * | 1998-12-17 | 2004-03-15 | Alza Corp | CONVERSION OF LIQUID-FILLED GELATIN CAPSULES INTO SYSTEMS WITH CONTROLLED ACTIVE RELEASE THROUGH MULTIPLE COATINGS |
AU2002225870B2 (en) * | 2000-11-03 | 2006-09-21 | Intarcia Therapeutics, Inc. | Method for short-term and long-term drug dosimetry |
-
2003
- 2003-06-25 AU AU2003256308A patent/AU2003256308B2/en not_active Ceased
- 2003-06-25 NZ NZ537628A patent/NZ537628A/en not_active IP Right Cessation
- 2003-06-25 ES ES03762060T patent/ES2295642T3/en not_active Expired - Lifetime
- 2003-06-25 CN CNB038185156A patent/CN100453130C/en not_active Expired - Fee Related
- 2003-06-25 KR KR1020047021083A patent/KR101046903B1/en active IP Right Grant
- 2003-06-25 CA CA2490544A patent/CA2490544C/en not_active Expired - Fee Related
- 2003-06-25 BR BR0312429-0A patent/BR0312429A/en not_active IP Right Cessation
- 2003-06-25 AT AT03762060T patent/ATE376854T1/en not_active IP Right Cessation
- 2003-06-25 MX MXPA05000224A patent/MXPA05000224A/en active IP Right Grant
- 2003-06-25 EP EP03762060A patent/EP1551493B1/en not_active Expired - Lifetime
- 2003-06-25 DE DE60317225T patent/DE60317225T2/en not_active Expired - Lifetime
- 2003-06-25 US US10/606,407 patent/US6939556B2/en not_active Expired - Lifetime
- 2003-06-25 WO PCT/US2003/020130 patent/WO2004002565A1/en active IP Right Grant
- 2003-06-25 JP JP2004517856A patent/JP4485945B2/en not_active Expired - Lifetime
-
2004
- 2004-03-17 TW TW093107021A patent/TW200531709A/en unknown
- 2004-12-23 IL IL165975A patent/IL165975A/en unknown
-
2005
- 2005-01-24 NO NO20050368A patent/NO20050368L/en not_active Application Discontinuation
- 2005-01-26 EC EC2005005578A patent/ECSP055578A/en unknown
- 2005-09-06 US US11/219,960 patent/US7112335B2/en not_active Expired - Lifetime
-
2006
- 2006-01-11 HK HK06100435A patent/HK1080402A1/en not_active IP Right Cessation
- 2006-01-25 ZA ZA200500744A patent/ZA200500744B/en unknown
- 2006-09-26 US US11/526,983 patent/US20070088337A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004002565A1 (en) | 2004-01-08 |
CN100453130C (en) | 2009-01-21 |
HK1080402A1 (en) | 2006-04-28 |
KR101046903B1 (en) | 2011-07-06 |
US7112335B2 (en) | 2006-09-26 |
KR20050026416A (en) | 2005-03-15 |
US20060111693A1 (en) | 2006-05-25 |
TW200531709A (en) | 2005-10-01 |
EP1551493A1 (en) | 2005-07-13 |
MXPA05000224A (en) | 2005-06-03 |
US20070088337A1 (en) | 2007-04-19 |
NO20050368L (en) | 2005-01-24 |
BR0312429A (en) | 2005-04-19 |
US20040019345A1 (en) | 2004-01-29 |
AU2003256308B2 (en) | 2008-07-03 |
JP2005530588A (en) | 2005-10-13 |
CA2490544C (en) | 2011-04-19 |
US6939556B2 (en) | 2005-09-06 |
ATE376854T1 (en) | 2007-11-15 |
CN1671439A (en) | 2005-09-21 |
AU2003256308A1 (en) | 2004-01-19 |
ECSP055578A (en) | 2005-04-18 |
IL165975A (en) | 2009-07-20 |
ZA200500744B (en) | 2006-03-29 |
JP4485945B2 (en) | 2010-06-23 |
ES2295642T3 (en) | 2008-04-16 |
DE60317225T2 (en) | 2008-05-29 |
IL165975A0 (en) | 2006-01-15 |
NZ537628A (en) | 2005-12-23 |
DE60317225D1 (en) | 2007-12-13 |
EP1551493B1 (en) | 2007-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2490544A1 (en) | Minimally compliant, volume efficient piston for osmotic drug delivery systems | |
JP2005530588A5 (en) | ||
WO2000040218A3 (en) | Osmotic delivery system having space efficient piston | |
CN101453982A (en) | Two-piece, internal-channel osmotic delivery system flow modulator | |
US4203442A (en) | Device for delivering drug to a fluid environment | |
WO2001045675A3 (en) | Valve for osmotic devices | |
US4559040A (en) | Segmented peristaltic pump chamber | |
ES2243738T3 (en) | OSMOTIC IMPLANT WITH MEMBRANE AND MEMBRANE RETENTION ORGAN. | |
CO4970812A1 (en) | OSMOTIC SUPPLY SYSTEMS, ASSEMBLY OF THE BODY OF THE OSMOTIC SUPPLY SYSTEM AND SYSTEM TO CONTROL THE SUPPLY RATE OF BENEFICIAL AGENTS OF THE OSMOTIC SUPPLY SYSTEM. | |
ES2671180T3 (en) | Plunger for medicinal hollow body and medicinal hollow body | |
KR20060017749A (en) | Osmotic pump with means for dissipating internal pressure | |
WO2005039668A3 (en) | Implantable drug delivery device for sustained release of therapeutic agent | |
DE69425828T2 (en) | OSMOTIC DEVICE WITH VAPOR-PERMEABLE COATING | |
NO307245B1 (en) | Disposable dispenser intended for medication | |
WO2007056131B1 (en) | Continuously sealing one way valve assembly and fluid delivery system formulations for use therein | |
JP2005255253A (en) | Capsule for storing, mixing and dispensing material | |
CA2489325A1 (en) | Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle | |
ES2586656T3 (en) | A process to transfer a substance between closed systems | |
EP2773414A1 (en) | Osmotically active vaginal delivery system | |
CA2492836A1 (en) | Administration device comprising an osmotic drive | |
CN107708608B (en) | Predetermined close liquid-based substance saves tubule and injection device and method using tubule | |
EP1904746A2 (en) | Fluid delivery device | |
BR9811670A (en) | Improvements related to containers for medicinal products. | |
WO1995013760A1 (en) | Gas driven controlled release device | |
WO2003096968A3 (en) | Oral osmotic controlled drug delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20210625 |